Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

('Mediclinic', the 'Company' or the 'Group')

26 July 2018

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting ('AGM') held on 25 July 2018, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholdersby way of poll. The results of the poll for each resolution were as follows:

TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTES WITHHELD

ORDINARY RESOLUTIONS

1.

To receive the Company's financial statements and the reports by the Directors and auditors

625,083,123

84.79

625,071,801

100.00

11,322

0.00

756,974

2.

To approve the Directors' Remuneration Report

624,930,678

84.77

584,591,036

93.54

40,339,642

6.46

909,418

3.

To declare a final dividend of 4.70 pence per ordinary share

625,551,249

84.85

625,538,743

100.00

12,506

0.00

288,848

4.

To elect Dr Ronnie van der Merwe as a Director

625,545,985

84.85

624,986,007

99.91

559,978

0.09

294,112

5.

To elect Dr Muhadditha Al Hashimi as a Director

625,545,570

84.85

625,118,233

99.93

427,337

0.07

294,527

6.

To elect Dr Felicity Harvey as a Director

625,546,210

84.85

625,119,604

99.93

426,606

0.07

293,887

7.

To re-elect Jurgens Myburgh as a Director

625,545,985

84.85

624,155,541

99.78

1,390,444

0.22

294,112

8.

To re-elect Dr Edwin Hertzog as a Director

623,687,848

84.60

607,348,527

97.38

16,339,321

2.62

2,152,247

9.

To re-elect Jannie Durand as a Director

625,264,107

84.81

612,530,823

97.96

12,733,284

2.04

575,989

10.

To re-elect Alan Grieve as a Director

622,786,782

84.48

621,642,338

99.82

1,144,444

0.18

3,053,315

11.

To re-elect Seamus Keating as a Director

622,785,782

84.47

622,271,752

99.92

514,030

0.08

3,054,315

12.

To re-elect Trevor Petersen as a Director

622,786,512

84.47

620,324,982

99.60

2,461,530

0.40

3,053,585

13.

To re-elect Desmond Smith as a Director

621,209,703

84.26

551,631,116

88.80

69,578,587

11.20

4,630,393

14.

To re-elect Danie Meintjes as a Director

625,545,985

84.85

603,084,758

96.41

22,461,227

3.59

294,112

15.

To re-appoint PricewaterhouseCoopers LLP as auditors of the Company

622,507,013

84.44

618,004,417

99.28

4,502,596

0.72

3,333,084

16.

To authorise the Audit and Risk Committee to determine the remuneration of the auditors

625,265,419

84.81

624,782,389

99.92

483,030

0.08

574,678

17.

To authorise the Directors to make political donations

624,054,992

84.65

560,842,274

89.87

63,212,718

10.13

1,785,104

18.

To authorise the Directors to allot ordinary shares

625,265,198

84.81

524,756,458

83.93

100,508,740

16.07

574,899

SPECIAL RESOLUTIONS

19.

To authorise the Directors to dis-apply the statutory pre-emption rights

625,262,700

84.81

590,059,495

94.37

35,203,205

5.63

577,397

20.

To authorise the Directors to dis-apply pre-emption rightsfor purposes of acquisitions or capital investments

625,263,385

84.81

591,029,782

94.52

34,233,603

5.48

576,711

21.

To approve the reduction in minimum notice period for general meetings (other than annual general meetings)

624,328,189

84.68

602,771,765

96.55

21,556,424

3.45

1,511,908

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDERON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

ORDINARY RESOLUTIONS

TOTAL SHARES VOTED

% OF ISSUED SHARE CAPITAL VOTED

VOTES FOR

%

VOTES AGAINST

%

VOTED WITHHELD

5.

To elect Dr Muhadditha Al Hashimi as a Director

369,163,066

76.77

368,735,729

99.88

427,337

0.12

294,527

6.

To elect Dr Felicity Harvey as a Director

369,163,706

76.77

368,737,100

99.88

426,606

0.12

293,887

10.

To re-elect Mr Alan Grieve as a Director

366,404,278

76.20

365,259,834

99.69

1,144,444

0.31

3,053,315

11.

To re-elect Mr Seamus Keating as a Director

366,403,278

76.20

365,889,248

99.86

514,030

0.14

3,054,315

12.

To re-elect Mr Trevor Petersen as a Director

366,404,008

76.20

363,942,478

99.33

2,461,530

0.67

3,053,585

13.

To re-elect Mr Desmond Smith as a Director

364,827,199

75.87

295,248,612

80.93

69,578,587

19.07

4,630,393

Notes:

1.

Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the 'For' total.

2.

A vote 'Withheld' is not a vote in law and is not counted in the calculation of the votes 'For' or 'Against' a resolution.

3.

The Company's total ordinary shares in issue (total voting rights) as at 25 July 2018 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.

4.

As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 5 to 6 and 10 to 13) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:

(a) the shareholders of the Company as a whole; and

(b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection athttp://www.morningstar.co.uk/uk/NSM.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company's website at http://ir.mediclinic.com.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.'

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

+44 (0)20 3727 1000

Sherryn Schooling - South Africa

+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers:Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

Attachments

  • Original document
  • Permalink

Disclaimer

Mediclinic International plc published this content on 26 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 July 2018 06:09:17 UTC